DK1515702T6 - Misbrugssikret indgivelsesform - Google Patents

Misbrugssikret indgivelsesform Download PDF

Info

Publication number
DK1515702T6
DK1515702T6 DK03735628.4T DK03735628T DK1515702T6 DK 1515702 T6 DK1515702 T6 DK 1515702T6 DK 03735628 T DK03735628 T DK 03735628T DK 1515702 T6 DK1515702 T6 DK 1515702T6
Authority
DK
Denmark
Prior art keywords
protected
abuse
submission form
aqueous liquid
administration form
Prior art date
Application number
DK03735628.4T
Other languages
English (en)
Other versions
DK1515702T3 (da
Inventor
Johannes Bartholomäus
Heinrich Kugelmann
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29737609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1515702(T6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of DK1515702T3 publication Critical patent/DK1515702T3/da
Application granted granted Critical
Publication of DK1515702T6 publication Critical patent/DK1515702T6/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03735628.4T 2002-06-17 2003-06-16 Misbrugssikret indgivelsesform DK1515702T6 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10227077 2002-06-17
DE10250083A DE10250083A1 (de) 2002-06-17 2002-10-25 Gegen Missbrauch gesicherte Darreichungsform
PCT/EP2003/006314 WO2003105808A1 (de) 2002-06-17 2003-06-16 Gegen missbrauch gesicherte darreichungsform

Publications (2)

Publication Number Publication Date
DK1515702T3 DK1515702T3 (da) 2009-01-12
DK1515702T6 true DK1515702T6 (da) 2022-04-11

Family

ID=29737609

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03735628.4T DK1515702T6 (da) 2002-06-17 2003-06-16 Misbrugssikret indgivelsesform

Country Status (11)

Country Link
EP (1) EP1515702B3 (da)
JP (2) JP2005534664A (da)
AT (1) ATE411007T1 (da)
AU (1) AU2003237944A1 (da)
CY (1) CY1108682T1 (da)
DE (2) DE10250083A1 (da)
DK (1) DK1515702T6 (da)
ES (1) ES2315505T7 (da)
PT (1) PT1515702E (da)
SI (1) SI1515702T1 (da)
WO (1) WO2003105808A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1908460A1 (de) 2002-11-22 2008-04-09 Grünenthal GmbH Verwendung von (1R,2R)-3-(2-Dimethylaminomethyl-cyclohexyl)-phenol zur Behandlung von Entzündungsschmerz
EP1782834A3 (en) * 2003-03-13 2007-08-01 Controlled Chemicals, Inc. Oxycodone conjugates with lower abuse potential and extended duration of action
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20050165038A1 (en) * 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
JP5259183B2 (ja) * 2004-07-01 2013-08-07 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用に対して保護された経口剤形
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
AR053304A1 (es) * 2004-07-01 2007-05-02 Gruenenthal Gmbh Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
CN102123701B (zh) 2008-05-09 2013-03-27 格吕伦塔尔有限公司 使用喷雾冻凝步骤制备中间粉末制剂以及最终固体剂型的方法
JP2012533585A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化感受性オピオイドのための不正使用防止剤形
NZ596667A (en) 2009-07-22 2013-09-27 Gruenenthal Chemie Hot-melt extruded controlled release dosage form
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
KR20130137627A (ko) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 음이온성 중합체를 포함하는 내변조성 투여형
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
NO2736497T3 (da) 2011-07-29 2018-01-20
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
CA2868142A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
AU2014273226B2 (en) 2013-05-29 2019-06-27 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
WO2015004245A1 (en) 2013-07-12 2015-01-15 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (de) * 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
WO1999032120A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
BR0212020A (pt) * 2001-08-06 2005-08-16 Euro Celtique Sa Formas de dosagem, métodos para impedir o abuso de uma forma de dosagem, métodos para impedir o desvio de uma forma de dosagem, métodos para o tratamento de dor e método de preparação de uma forma de dosagem
KR20040060917A (ko) * 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
KR20190026065A (ko) 2010-07-23 2019-03-12 그뤼넨탈 게엠베하 ３-(３-디메틸아미노-１-에틸-２-메틸-프로필)-페놀의 염 또는 공결정

Also Published As

Publication number Publication date
ATE411007T1 (de) 2008-10-15
DE50310649D1 (de) 2008-11-27
CY1108682T1 (el) 2014-04-09
ES2315505T3 (es) 2009-04-01
ES2315505T7 (es) 2022-04-07
EP1515702A1 (de) 2005-03-23
JP2011251982A (ja) 2011-12-15
JP2005534664A (ja) 2005-11-17
EP1515702B1 (de) 2008-10-15
DK1515702T3 (da) 2009-01-12
SI1515702T1 (sl) 2009-04-30
WO2003105808A1 (de) 2003-12-24
PT1515702E (pt) 2008-12-29
DE10250083A1 (de) 2003-12-24
EP1515702B3 (de) 2022-01-12
AU2003237944A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
DK1515702T6 (da) Misbrugssikret indgivelsesform
SV2003001106A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco ref.pc11846
EA200600696A1 (ru) Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств
BR0006005A (pt) Composição estável de óleo em glicerinatopicamente aplicável
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
EA200200858A1 (ru) Фармацевтические композиции, содержащие ингибиторы гликогенфосфорилазы
BRPI0410555A (pt) preparação sólida
MXPA06010767A (es) Composicion farmaceutica anhidra que asocia un agente siliconado y principio activo solubilizado.
WO2005017097A3 (en) Quorum sensing and biofilm formation
DK1327143T3 (da) Krystalstruktur af BACE og anvendelse deraf
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
ATE509854T1 (de) Verbesserungen in behältern oder diese betreffend
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
BR0013012A (pt) Composição contendo substância ativa, sua produção e seu uso
NO20020829L (no) Ny anvendelse av docetaxel for behandling av hepatoma
BR0002152A (pt) Composições para o tratamento dos cabelos com polìmeros de sacarìdeos insaturados, de ácidos de sacarìdeos insaturados ou seus derivados
FR2795315B1 (fr) Compositions cosmetiques contenant un polymere amphotere et un agent antipelliculaire et leurs utilisations
MA27102A1 (fr) Composition pharmaceutique orodispersible d'ivabradine
ATE297738T1 (de) Verfahren zur erhöhung der wachsamkeit durch verabreichung von vomeropherin und vomeropherin emittierende alarmvorricthung
WO2002056840A3 (de) Kosmetisches und/oder pharmazeutisches mittel acylierte aminosaüre enthaltend.
MA28292A1 (fr) Forme posologique solide
BRPI0516957A (pt) formulação farmacêutica estabilizada de agente de leucotrieno b4 (ltb4)
FR2848829B1 (fr) Composition cosmetiques contenant un tensioactif amphotere et une silicone et leurs utilisations
SE0201762D0 (sv) Ozone Solutions
YU102403A (sh) Postupci za dizajniranje leka, baziranog na strukturi, za identifikovanje inhibitora d-ala-d-ala ligaze, kao antibakterijskih lekova